Search Results
Jan 12, 2026, 09:03 ET NowThis Promotes Matt Grandchamp to SVP, Head of Revenue Amid Breakout Year of Growth
has not only driven tremendous growth this year, but also positioned our company to pioneer the next generation of media monetization. Matt has the rare combination of strategic vision, creativity, and executional excellence that inspires teams and sets new standards for our industry."Since joining
More news about: NowThis
Jan 12, 2026, 09:00 ET Debut Appoints Derek Wanner as Chief Commercial Officer Amid Rapid Growth of Its Formulation Business
business, expand strategic partnerships, and work closely with industry-leading brands to power cutting-edge innovation in beauty."Derek brings a rare combination of commercial rigor, formulation expertise, and deep industry relationships," said Joshua Britton, PhD, Founder and CEO of Debut. "As demand
More news about: Debut Biotechnology
Jan 12, 2026, 09:00 ET Neurelis Provides Business Update Highlighting Transformational 2025 Results
BA-1049), an investigational, Phase 1 new chemical entity Rho kinase (ROCK) inhibitor, for the treatment of cerebral cavernous malformations (CCMS), a rare disorder of the central nervous system (CNS). For more information on Neurelis, please visit
More news about: Neurelis, Inc.
Jan 12, 2026, 08:42 ET BidItUp Announces Private Treaty Sale of Dexter Stamping Company -- Complete Turnkey Automotive Manufacturing Facility
represents a rare opportunity to acquire a complete, operating manufacturing platform with a current replacement and setup value exceeding $50 million."Opportunities to acquire a fully built, production-ready operation of this caliber are exceedingly rare," said Tara Shaikh,
More news about: BidItUp Auctions Worldwide
Jan 12, 2026, 08:32 ET MOND™ Products Relaunches Luminous Repair Masque (LRM)
deliver immediate improvement while supporting long-term hair health.At the core of LRM are two key innovations. The first is Anorthosite, a rare mineral found on Earth and on the surface of the moon. In hair-care formulations, Anorthosite enhances shine, supports hair structure, and contributes
More news about: MOND™
Jan 12, 2026, 08:30 ET PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. PTC's ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a
More news about: PTC Therapeutics, Inc.
Jan 12, 2026, 08:05 ET PIERRE FABRE PHARMACEUTICALS STATEMENT REGARDING RECEIPT OF COMPLETE RESPONSE LETTER FOR TABELECLEUCEL BIOLOGICS LICENSE APPLICATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION
concerned that this decision may have far-reaching consequences for the development of rare disease treatments, effectively creating barriers for generating clinical evidence within a unique patient population with ultra-rare conditions thereby significantly delaying—or preventing altogether— patient access
More news about: Pierre Fabre Pharmaceuticals
Jan 12, 2026, 08:00 ET Cytotheryx Secures Lead Investor for $60M Series A; Confirms Debt Financing to Expand Facilities
Cytotheryx's differentiated platform addresses a substantial unmet need in acute, chronic, and rare liver diseases by delivering a scalable supply of clinically relevant, fully functional human hepatocytes, or liver cells, and leveraging those cells
More news about: Cytotheryx, Inc.
Jan 12, 2026, 08:00 ET Cohen & Company Announces Appointment of Senior Leadership to Expand Energy and Energy Transition Capabilities
adapt portfolios to changing market and capital allocation dynamics.Having led digital asset, quantum, and rare earth SPAC IPOs in 2025, Cohen & Company Capital Markets, the leading SPAC bank globally last year, is doubling down on its vision and expertise
More news about: Cohen & Company Inc
Jan 12, 2026, 08:00 ET Minaris and Genetix Biotherapeutics Expand Manufacturing Partnership to Support Commercial Supply for LYFGENIA™ (lovotibeglogene autotemcel)
provider, and Genetix Biotherapeutics Inc., a commercial-stage biotechnology company dedicated to delivering genetic therapies for patients with severe rare diseases, today announced an expanded manufacturing partnership to increase commercial-scale production of LYFGENIA, Genetix's FDA-approved, one-time
More news about: Minaris Advanced Therapies
Jan 12, 2026, 08:00 ET Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference
RRPRRP is a rare, debilitating, and potentially life-threatening disease of the upper and lower respiratory tract caused by chronic HPV 6 or HPV 11 infection. RRP can lead to severe voice disturbance, compromised airways, and recurrent post-obstructive pneumonia. Although rare, RRP has the potential
More news about: Precigen, Inc.
Jan 12, 2026, 08:00 ET Novita Pharmaceuticals Announces FDA Orphan Drug Designation Granted to NP-G2-044 for the Treatment of Pancreatic Cancer
continuing advancement of NP-G2-044 to address the high unmet need."Orphan Drug Designation is granted to investigational therapies intended to treat rare diseases affecting fewer than 200,000 patients in the United States. The designation provides development incentives, including eligibility for tax
More news about: Novita Pharmaceuticals, Inc.
Jan 12, 2026, 08:00 ET BostonGene Recognized by Frost & Sullivan for 2025 Global Technology Innovation Leadership in AI-Driven Precision Oncology Solutions
evaluates market participants across two core dimensions: strategy effectiveness and strategy execution. BostonGene excels in both, demonstrating a rare ability to synchronize visionary strategic initiatives with real-world market demand while executing at a global scale with efficiency and consistency.
More news about: Frost & Sullivan
Jan 12, 2026, 08:00 ET BostonGene Recognized by Frost & Sullivan for 2025 Global Technology Innovation Leadership in AI-Driven Precision Oncology Solutions
evaluates market participants across two core dimensions: strategy effectiveness and strategy execution. BostonGene excels in both, demonstrating a rare ability to synchronize visionary strategic initiatives with real-world market demand while executing at a global scale with efficiency and consistency.
More news about: Frost & Sullivan
Jan 12, 2026, 07:00 ET Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity
of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential
More news about: Viking Therapeutics, Inc.
Jan 12, 2026, 07:00 ET SOPHiA GENETICS Provides Preliminary Fourth Quarter and Full Year 2025 Financial Results, Initiates 2026 Guidance, and Announces Executive Transition Plan
healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time,
More news about: SOPHiA GENETICS
Jan 12, 2026, 07:00 ET SOPHiA GENETICS Provides Preliminary Fourth Quarter and Full Year 2025 Financial Results, Initiates 2026 Guidance, and Announces Executive Transition Plan
healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time,
More news about: SOPHiA GENETICS
Jan 12, 2026, 07:00 ET Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026
symptom score (Abs-TSS) over 24 weeks relative to baseline.About MyelofibrosisMyelofibrosis is a rare blood cancer that affects approximately 20,000 patients in the United States and 17,000 patients in the European Union1. The disease causes
More news about: Karyopharm Therapeutics Inc.
Jan 12, 2026, 05:46 ET Two-Time Cancer Survivor Reveals How She Discovered Her Path to Healing After Her Life Was "Uprooted"
journal entries, and real-time reflections, the prologue sets the stage with the initial diagnosis in 2014 when doctors informed Dano that she had a rare form of ovarian cancer, a granulosa cell tumor, which accounts for less than 5% of all ovarian cancer cases, with a nearly 100% recurrence rate. The
More news about: Balboa Press
Jan 12, 2026, 05:00 ET Windrose Consulting Group Expands Greater China and APAC Expertise with Acquisition of Zenith Access Network
Market Access solutions across multiple therapeutic areas, including oncology, cardiovascular disease, neurology, endocrinology, infectious diseases, rare diseases, and ophthalmology. To learn more, visit zenith-access.com.
More news about: Windrose Consulting Group
Jan 12, 2026, 05:00 ET Windrose Consulting Group Expands Greater China and APAC Expertise with Acquisition of Zenith Access Network
Market Access solutions across multiple therapeutic areas, including oncology, cardiovascular disease, neurology, endocrinology, infectious diseases, rare diseases, and ophthalmology. To learn more, visit zenith-access.com.About
More news about: Windrose Consulting Group
Jan 12, 2026, 03:01 ET Fewer than One in Five Companies Have a Dedicated Geopolitics Department
geopolitics episodically. Leadership attention is high, but embedded routines to link geopolitical developments to core business metrics and actions remain rare."Too many companies treat geopolitics as a headline issue rather than a business capability," said Nikolaus Lang, Global Leader of the BCG Henderson
More news about: Boston Consulting Group (BCG)
Jan 11, 2026, 19:00 ET Argo Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
molecule candidates targeting a wide range of indications, including cardiovascular diseases, viral infections, metabolic conditions, and specialty/rare diseases. Currently, Argo Biopharma has six RNAi candidates in clinical development.For more information, visit
More news about: Argo Biopharmaceutical Co., Ltd
Jan 11, 2026, 15:48 ET Rich Sparkle Holdings Closes Acquisition of TikTok Icon Khaby Lame's Core Company
languages and cultures without translation.Today, his global following totals 360 million across platforms, making him one of the rare creators who can drive attention in multiple major regions at once. Industry observers describe him as a "global-tier traffic entrance"—a scarce
More news about: Rich Sparkle Holdings
Jan 11, 2026, 15:00 ET REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program
/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) highlighted progress and upcoming anticipated milestones across its pipeline of AAV gene therapies for rare and retinal diseases. "2026 is set to be a transformative year for REGENXBIO, as we enter commercial stage with two near-term catalysts from
More news about: REGENXBIO Inc.